This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n22http://linked.opendata.cz/resource/drugbank/drug/DB00041/identifier/uniprotkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00041/identifier/genbank/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/AHFS/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00041/identifier/wikipedia/
n17http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00041/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n10http://linked.opendata.cz/resource/drugbank/dosage/
n5http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00041/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n25http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00041/identifier/national-drug-code-directory/
n12http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n18http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n26http://www.rxlist.com/cgi/generic2/
n14http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00041
rdf:type
n3:Drug
n3:description
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
n3:dosage
n10:271B414E-363D-11E5-9242-09173F13E4C5 n10:271B414F-363D-11E5-9242-09173F13E4C5 n10:271B4150-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
13 min-85 min
n3:indication
For treatment of adults with metastatic renal cell carcinoma.
owl:sameAs
n5:DB00041 n25:DB00041
dcterms:title
Aldesleukin
adms:identifier
n16:Aldesleukin n20:M11144 n21:DB00041 n22:P60569 n23:0078-0495-61 n24:PA448081
n3:mechanismOfAction
Aldesleukin binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.
n3:packager
n17:271B414B-363D-11E5-9242-09173F13E4C5 n17:271B4149-363D-11E5-9242-09173F13E4C5 n17:271B414A-363D-11E5-9242-09173F13E4C5 n17:271B4147-363D-11E5-9242-09173F13E4C5 n17:271B4148-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.
n3:synonym
T-cell growth factor IL-2 Interleukin-2 precursor TCGF
n3:volumeOfDistribution
0.18 l/kg
n8:hasAHFSCode
n9:10-00-00
n3:synthesisReference
Hans-Ake Fabricius, Roland Stahn, "Serum-free and mitogen-free T-cell growth factor and process for making same." U.S. Patent US4464355, issued May, 1971.
n18:hasConcept
n19:M0220038
foaf:page
n7:aldesleukin.html n26:aldesleukin.htm
n3:Molecular-Formula
n14:271B4154-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n14:271B4153-363D-11E5-9242-09173F13E4C5
n8:hasATCCode
n13:L03AC01
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
85898-30-2
n3:category
n3:containedIn
n12:271B414C-363D-11E5-9242-09173F13E4C5 n12:271B414D-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n14:271B4151-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n14:271B4152-363D-11E5-9242-09173F13E4C5